Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Retained Earnings came in at $259.7 million in Q1 2026, up 1256.24% YoY from $19.2 million in Q1 2025, and up 2027.8% on a QoQ basis from -$13.5 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Retained Earnings (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Retained Earnings data on file, last reported at $259.7 million in Q1 2026.
- Quarterly Retained Earnings rose 1256.24% year-over-year to $259.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259.7 million (up 1256.24% YoY) and the FY2025 annual result came in at -$13.5 million, up 93.08% from the prior year.
- Retained Earnings advanced to $259.7 million in Q1 2026, from -$13.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $259.7 million in Q1 2026 to a low of -$804.9 million in Q1 2022.
- A 5-year average of -$152.2 million and a median of -$1.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 16184.95% — and 2025, when it soared 4217.83%.
- Tracing BMRN's Retained Earnings over 5 years: stood at -$789.2 million in 2022, then soared by 96.35% to -$28.8 million in 2023, then plunged by 576.31% to -$194.7 million in 2024, then jumped by 93.08% to -$13.5 million in 2025, then surged by 2027.8% to $259.7 million in 2026.
- The last three Retained Earnings figures came in at $259.7 million (Q1 2026), -$13.5 million (Q4 2025), and $200.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 304.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 304.50 Mn |
| Mar 31, 2026 | 259.73 Mn |
| Dec 31, 2025 | -13.47 Mn |
| Sep 30, 2025 | 200.78 Mn |
| Jun 30, 2025 | 231.52 Mn |
| Mar 31, 2025 | 19.15 Mn |
| Dec 31, 2024 | -194.70 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 26.80 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -28.79 Mn |
| Sep 30, 2023 | 6.26 Mn |
| Jun 30, 2023 | -18.62 Mn |
| Mar 31, 2023 | -738.35 Mn |
| Dec 31, 2022 | -789.20 Mn |
| Sep 30, 2022 | 30.75 Mn |
| Jun 30, 2022 | -777.23 Mn |
| Mar 31, 2022 | -804.89 Mn |
| Dec 31, 2021 | 14.43 Mn |
| Sep 30, 2021 | 10.24 Mn |